Q2 saw robust revenue and margin growth, led by MRD clinical and pharma segments, with blood-based and community testing adoption accelerating. Guidance was raised for MRD revenue and clinical volumes, while strategic separation of Immune Medicine and capital restructuring further strengthened the outlook.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.